Patent ID: 6110911
Filing Date: 2000-08-29
Classification: C07D

Abstract:
A method of treating convulsions which comprises administering a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, whereinR is a mono, bi-cycle spiro ring non-aromatic unsubstituted or substituted by from 1 to 4 subtituents, R is attached to the quinoxaline ring through (--CH.sub.2).sub.n and at the a- or b-position andR is ##STR92## of from 4 to 7 atom; or ##STR93## of from 8 to 12 atoms wherein R.sub.11 is from 1 to 4 substituents independently selected fromhydrogen,hydroxy,hydroxyalkyl,alkyl,alkoxy,alkoxyalkyl,--NR.sub.13 R.sub.14,aminoalkyl,alkenyl,alkynyl,thiol,alkythioalkyl,aryl,aralkyl,heteroaryl,heteroalkyl,cycloalkyl,--SO.sub.2 R.sub.15,--SO.sub.2 NR.sub.13 R.sub.14,--(CH.sub.2).sub.n SO.sub.2 NR.sub.13 R.sub.14, and--(CH.sub.2).sub.n SO.sub.2 R.sub.15,wherein R.sub.13 and R.sub.14 are independently selected fromhydrogen,alkyl,cycloalkyl,heterocycle which is a ring with from 4 to 7 members, with up to 4 heteroatoms selected from N, O, and S,aralkyl, andaryl;R.sub.15 is hydroxy, alkoxy, --NR.sub.13 R.sub.14, or haloalkyl;R.sub.11 may be 2 substituents attached at the same carbon;X and Y are each independently carbon which is substituted by hydrogen, halogen, haloalkyl, alkyl, alkoxy, alkoxyalkyl, NR.sub.13 R.sub.14, aminoalkyl, aralkyl, aryl, heteroaryl, heteroaralkyl, cycloalkyl, heterocycle which is a ring with from 4 to 7 members, with up to 4 heteroatms selected from N, O, and S, hydroxy, hydroxyalkyl,--O--,--S--,--SO--,--SO.sub.2 --,--NR.sub.16 --;wherein R.sub.16 is alkyl, hydrogen, aralkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, hetercycle which is a ring with from 4 to 7 heteroatoms selected from N, O, and S, --C(O)OR.sub.17, --C(O)R.sub.17, --SO.sub.2 R.sub.18, --SO.sub.2 NR.sub.19 R.sub.20, --CH.sub.2 SO.sub.2 R.sub.18, and --CH.sub.2 SO.sub.2 NR.sub.19 R.sub.20,wherein R.sub.17 is alkyl, aralkyl, cycloalkyl, heterocycle which is a ring with from 4 to 7 heteroatoms selected from N, O, and S, aryl, or heteroaryl;R.sub.18 is alkyl, aralkyl, hydroxyl, or alkoxy;R.sub.19 and R.sub.20 are each independently hydrogen and alkyl;R.sub.1 is hydrogen,alkyl,aralkyl,carboxyalkyl,phosphoroalkyl, orphosphonoalkyl,R.sub.7 is hydrogen, hydroxy, or amino,R.sub.3 and R.sub.4 are each independentlyhydrogen,alkyl,cycloalkyl,alkenyl,halogen,haloalkyl,nitro,cyano,SO.sub.2 CF.sub.3,CH.sub.2 SO.sub.2 R.sub.6,(CH.sub.2).sub.m CO.sub.2 R.sub.6,(CH.sub.2).sub.m CONR.sub.7 R.sub.8,(CH.sub.2).sub.m SO.sub.2 NR.sub.7 R.sub.8, orNHCOR.sub.6 wherein m is an integer of from 0 to 4, and R.sub.6, R.sub.7, and R.sub.8 are each independently selected from hydrogen, alkyl, cycloalkyl, haloalkyl, or aralkyl;R.sub.5 is hydrogen,alkyl,alkenyl,cycloalkyl,halogen,haloalkyl,aryl,aralkyl,heteroaryl,nitro,cyano,SO.sub.2 CF.sub.2,(CH.sub.2).sub.m CO.sub.2 R.sub.9,(CH.sub.2).sub.m CONR.sub.9 R.sub.10,SONR.sub.9 R.sub.10, orNHCOR.sub.9 ;wherein m is an integer of from 0 to 4;R.sub.9 and R.sub.10 are each independently hydrogen, alkyl, cycloalkyl, or aralkyl; andR.sub.5 may be at the a-position and R--(CH.sub.2)-- at the b-position on the ring to a patient in need of said treatment.